Here is IP Think Tank’s weekly selection of top Pharma & Biotech intellectual property news breaking in the blogosphere and internet.

Please join the discussion by adding your comments on any of these stories, and please do let us know if you think we’ve missed something important, or if there is a source you think should be monitored.

You can separately subscribe to the IP Think Tank Global Week in Review at the Subscribe page: http://thinkipstrategy.com/subscribe/

Temodar (Temozolomide) – US: District Court Delaware: Temador patent unenforceable due to prosecution laches and inequitable conduct: Cancer Research Tech v Barr Labs (Docket Report) (Patent Baristas) (IP Factor)

Mirapex (Pramipexole) – US: CAFC: The metes and bounds of obviousness-type double patenting: Boehringer Ingelheim Int’l. v. Barr Laboratories, Inc. and Mylan Pharma (Patent Docs) (Patently-O)

EU: ‘Victory’ against biopiracy – EPO revokes Schwabe Pharmaceuticals’ pelargonium extract patent (Spicy IP) (IP Watch)

Another case for indigenous knowledge protection, but how? (Afro-IP)

When Harry met generic Sally: The proprietary/generic courtship continues (IP finance) 

China / India: Incremental pharmaceutical inventions in China and India: ‘No need to reinvent the wheel’ (IP Dragon)

India: National Biodiversity Authority invites comments on draft amendments (Spicy IP)

EU: New Parliament group monitors EU trade pacts’ impact on poor’s medicines access (IP Watch)

EU: ‘Victory’ against biopiracy – EPO revokes Schwabe Pharmaceuticals’ pelargonium extract patent (Spicy IP) (IP Watch)

US: Interim procedure for requesting a (free) patent term adjustment recalculation from the PTO (Patently-O) (Patently-O) (Patent Docs)

US: Invalidity of the extension of a patent term: (Patently-O)

US: Follow-on biologics news: BIO CEO asks President to focus on unresolved issues in health care debate; 38 patients groups and research universities back 12-year data exclusivity period; NATF says patient safety should be top priority when crafting biosimilar regulatory pathway (Patent Docs)

US: Will the nightmare for biotech prep/pros never end? – patenting biomarkers (Patents4Life)

US: Everybody knows – The Boston Globe weighs in on gene patenting (Patent Docs)

US: Requests for orphan drug designation explode in 2009; but designation success rate is low (FDA Law Blog)

US: Taking stock of FDA’s 180-day exclusivity forfeiture decisions – a forfeiture scorecard (FDA Law Blog)

US: Second settlement announced in Stinski patent dispute (Patent Docs)

Angiomax (Bivalirudin) – US: The Medicines Company sues PTO and FDA over Angiomax patent term extension decisions (FDA Law Blog)

Bordetella pertussis vaccines – UK: EWHC dismisses appeal against UK IPO finding appeal filed prematurely: Medeva BV v The Comptroller General of Patents (EPLAW) (PatLit)

CircoFLEX PCV2 vaccine – US: District Court Connecticut dismisses Protein Sciences from porcine circovirus vaccine suit (Patent Docs)

Effexor (Venlafaxine) – US: FDA denies petition on ‘original NDA’ patent certification issue (FDA Law Blog)

Gestrol (Megestrol) – Poland: GESTROL is not always similar to GESTROLTEX (Class 46)

Grazax (SQ-T) – France / Netherlands: More on adjuvants – Gravax SPC rejection/annulment (The SPC Blog)

Humira (Adalimumab) – India: Abbott’s Humira patent unilaterally revoked by Indian Patent Office (Spicy IP)

Mirapex (Pramipexole) – US: CAFC: The metes and bounds of obviousness-type double patenting: Boehringer Ingelheim Int’l. v. Barr Laboratories, Inc. and Mylan Pharma (Patent Docs) (Patently-O)

Omnicef (Cefdinir) – US: CAFC on whether a product-by-process claim is infringed by an identical product made by different process: Abbott Labs v Sandoz (IP Frontline)

Pertussis vaccines – UK: EWHC dismisses Medeva appeal against pertussis vaccines SPCs refusal (The SPC Blog)

Plavix (Clopidogrel) – Canada: Adding some obvious flexibility: Apotex Inc v Sanofi-Synthelabo Canada Inc (IP Osgoode)

Rapamune (Rapamycin) – US: District Court Delaware: Claiming analogs unknown to inventors renders patents invalid for lack of written description and enablement: Boston Scientific Corporation et al. v. Johnson & Johnson Inc. et al. (Docket Report)

Sustiva (Efavirenz) – US: Mylan and Matrix fail in bid to dismiss Sustiva case brought by Bristol Myer Squibb (Patent Docs)

Temodar (Temozolomide) – US: District Court Delaware: Temador patent unenforceable due to prosecution laches and inequitable conduct: Cancer Research Tech v Barr Labs (Docket Report) (Patent Baristas) (IP Factor)

Viread (Tenofovir) – US: Gilead Sciences announces notification of Teva’s ANDA filing for Viread (SmartBrief)